Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer
Autor: | Margherita Ratti, Jens C. Hahne, Michele Ghidini, Milko Mirchev, Nicola Valeri, Andrea Lampis, Ali Fuat Okuducu |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Gastrointestinal tumors lcsh:QH426-470 pancreatic cancer Review mismatch repair system Cancer Vaccines Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Immune system Pancreatectomy Internal medicine Pancreatic cancer Antineoplastic Combined Chemotherapy Protocols Genetics Medicine Humans immune-based therapy Precision Medicine Immune Checkpoint Inhibitors Genetics (clinical) Clinical Trials as Topic business.industry Patient Selection Microsatellite instability Cancer Treatment options medicine.disease Prognosis Colorectal Neoplasms Hereditary Nonpolyposis Lynch syndrome digestive system diseases Pancreatic Neoplasms Survival Rate lcsh:Genetics 030104 developmental biology Chemotherapy Adjuvant 030220 oncology & carcinogenesis Mutation Microsatellite Instability Immunotherapy Neoplasm Recurrence Local business Aggressive malignancies |
Zdroj: | Genes Genes, Vol 12, Iss 33, p 33 (2021) |
ISSN: | 2073-4425 |
Popis: | Pancreatic cancer is one of the most aggressive malignancies with limited treatment options thus resulting in high morbidity and mortality. Among all cancers, with a five-year survival rates of only 2–9%, pancreatic cancer holds the worst prognostic outcome for patients. To improve the overall survival, an earlier diagnosis and stratification of cancer patients for personalized treatment options are urgent needs. A minority of pancreatic cancers belong to the spectrum of Lynch syndrome-associated cancers and are characterized by microsatellite instability (MSI). MSI is a consequence of defective mismatch repair protein functions and it has been well characterized in other gastrointestinal tumors such as colorectal and gastric cancer. In the latter, high levels of MSI are linked to a better prognosis and to an increased benefit to immune-based therapies. Therefore, the same therapies could offer an opportunity of treatment for pancreatic cancer patients with MSI. In this review, we summarize the current knowledge about immune-based therapies and MSI in pancreatic cancer. |
Databáze: | OpenAIRE |
Externí odkaz: |